Innovation Portfolio Management: How to Balance Explore and Exploit Without Killing Growth (2026)

I want to start with a number that should concern you.

At more than 40 industrial companies where I’ve reviewed innovation budgets, the average allocation to genuine explore projects (new business models, new markets, unproven technologies) is between 5% and 10%. The remaining 90-95% funds core product improvements, cost reductions, and line extensions.

Leadership at every one of those companies said innovation was a strategic priority. Most had it in their mission statement. Several had Chief Innovation Officers. But the budget told a different story.

This is not a leadership failure. It’s a system failure. Without explicit portfolio governance, the present always beats the future. The sales team needs product updates to close this quarter’s deals. Operations needs cost savings to hit margin targets. Customer service needs bug fixes. Every one of those requests is urgent, measurable, and connected to someone’s bonus. The explore project testing a new business model for a market that doesn’t exist yet has none of those advantages, and it gets cut first every time.

Innovation portfolio management exists to solve this specific problem. Not with better frameworks, though frameworks help, but with better governance. I use several: the Business Portfolio Map, the Three Horizons, the Innovation Ambition Matrix. Each answers a different question. But the framework is never what determines whether a company’s portfolio delivers results. The governance system is.

This guide covers which frameworks work in which situations, how governance makes or breaks everything, and the manufacturing-specific reality that most portfolio advice, written for software companies, completely ignores. If your Business Model Canvas designs the individual models, your Value Proposition Canvas sharpens the customer focus, and testing business ideas validates the assumptions, then innovation portfolio management is the discipline of managing the whole collection of bets.

What Is Innovation Portfolio Management?

Innovation portfolio management is the practice of managing a company’s entire collection of innovation initiatives as a coordinated portfolio rather than a set of independent projects. It answers four questions that project management alone cannot:

1. Are we investing in the right mix of innovation? Core improvements, adjacent expansions, and transformational bets, in what proportion?
2. Are we investing enough in the future? Or is quarterly pressure consuming all resources for incremental improvements?
3. Which projects should we kill? Not because they failed, but because the portfolio needs rebalancing.
4. How do we make these decisions systematically? Not once a year in a strategy offsite, but through a governance rhythm that keeps the portfolio aligned with strategy.

This is different from project portfolio management, which focuses on execution efficiency: are projects on time, on budget, and on scope? Innovation portfolio management sits above that. It asks whether you’re doing the right projects, not just whether you’re doing projects right.

The core tension in every innovation portfolio is between explore and exploit. Exploit means optimising what you have: improving existing products, cutting costs, expanding into known markets with known offerings. Explore means investing in the uncertain: testing new business models, entering unfamiliar markets, developing technologies that might not work. Every company needs both. Almost every company gets the balance wrong.

Charles O’Reilly and Michael Tushman called this the challenge of the “ambidextrous organization“, a company that can simultaneously exploit current business models while exploring new ones. Their research at Stanford and Harvard showed that companies who structurally separated explore and exploit units outperformed those that tried to do both within the same teams. But separation alone isn’t enough. You also need a portfolio-level view that coordinates the two.

That’s where innovation portfolio management comes in. Without it, explore starves. Every time.

Why explore always loses without portfolio management

The numbers are predictable. I’ve reviewed innovation budgets at more than 40 industrial companies. The pattern repeats: leadership says innovation matters, but when I look at actual spending, 90-95% goes to core improvements and extensions. The remaining 5-10% is labelled “innovation” but mostly funds incremental product updates that the engineering team was going to do anyway.

This isn’t because leaders are dishonest about wanting innovation. It’s because exploit has built-in advocacy. The sales team needs product improvements to close deals this quarter. Operations needs cost reductions to hit margin targets. The customer service team needs bug fixes. Every one of those requests is urgent, measurable, and connected to someone’s bonus.

Explore has no such advocates. A project exploring a new business model for subscription-based industrial services doesn’t have customers yet. It doesn’t have revenue. It doesn’t have a champion in the quarterly business review. And when budgets get tight, which they always do, explore is the first thing cut.

Innovation portfolio management exists to counteract this gravitational pull toward the present. It creates a system where explore projects have protected budgets, clear stage-gates, and explicit governance that treats “we learned this assumption is false” as progress rather than failure.

The Frameworks: What They Do and When They Mislead

Four frameworks dominate the innovation portfolio management conversation. Each serves a different purpose, and most companies pick one without understanding what the others offer. I use all four, in different situations, for different questions.

The Business Portfolio Map (Osterwalder)

Alexander Osterwalder and the Strategyzer team introduced the Business Portfolio Map in The Invincible Company (2020). It maps each business model in your portfolio on two axes: return (revenue, profit, or strategic value) and innovation risk (how validated is the business model?).

The result is a visual portfolio where you can see your cash cows (high return, low risk), your growth engines (validated models scaling up), and your explore bets (high risk, low return, for now). You can also spot what Osterwalder calls the “death zone”, business models with declining returns and no replacement in the pipeline.

What it does well: – Creates a visual snapshot that leadership teams understand immediately – Forces conversation about risk exposure: “We have eight business models, and seven of them are in the exploit zone” – Maps directly to the Business Model Canvas, each dot on the portfolio map represents a full BMC – Highlights portfolio imbalance in a way that spreadsheets don’t

Where it needs adaptation: – It’s a snapshot, not a governance system. Mapping your portfolio doesn’t tell you what to do next. – Doesn’t include allocation budgets. You know your portfolio is imbalanced, but the map doesn’t tell you how much to invest where. – Doesn’t address kill criteria. When should a project move from “explore bet” to “cancelled”? – The original version doesn’t account for industry-specific constraints, like the fact that in manufacturing, an “explore” project might cost €2M just to get a prototype.

For a deeper assessment, see What Is the Business Portfolio Map? A Practitioner’s Assessment.

I use the Business Portfolio Map at the start of an engagement, it’s the fastest way to get a leadership team aligned on what their portfolio actually looks like. But I never stop there. The map starts the conversation. The governance system continues it.

The Three Horizons Framework (McKinsey)

The Three Horizons model, originally from McKinsey’s The Alchemy of Growth (1999), categorises innovation into three time-based horizons:

• Horizon 1: Core business. Generating today’s revenue and profit. Focus: optimise, extend, defend.
• Horizon 2: Emerging opportunities. Building tomorrow’s growth engines. Focus: scale, invest, build capability.
• Horizon 3: Future bets. Exploring the day after tomorrow. Focus: experiment, learn, stay cheap.

What it does well: – Simple enough that boards understand it in two minutes – Creates urgency: “If we only invest in H1, what happens when H1 declines?” – Useful for annual planning and multi-year strategy conversations – Provides clear language for different types of innovation investment

Where it misleads: – Implies a linear progression (H3 > H2 > H1) that doesn’t reflect reality. Some H3 ideas jump straight to market. Some H2 ideas regress to H3. – The time-based framing suggests you can predict when horizons will mature. In manufacturing, development cycles are 3-5 years, your H2 looks a lot like someone else’s H1 on the calendar. – Gives boards the false comfort that they’re “managing all three horizons” when in practice 95% of resources go to H1. – Doesn’t provide governance mechanisms. Knowing you need H3 projects doesn’t tell you how to fund them, review them, or kill them.

I use Three Horizons in board presentations and annual strategy sessions, it’s the right tool for creating strategic urgency. But I never use it for portfolio governance. For that, you need something more operational.

For an honest deep-dive, see Three Horizons of Innovation: A Practitioner’s Honest Assessment.

The Innovation Ambition Matrix (Nagji & Tuff)

Bansi Nagji and Geoff Tuff published “Managing Your Innovation Portfolio” in the Harvard Business Review in 2012. Their Innovation Ambition Matrix categorises innovation across two dimensions: how new the market is, and how new the offering is. This creates three zones:

• Core innovation: Existing products for existing markets. Optimise and extend.
• Adjacent innovation: Expand into related markets or add capabilities to existing products.
• Transformational innovation: New products for new markets. New capabilities, new customers, new everything.

Their famous finding: companies that allocated roughly 70% to core, 20% to adjacent, and 10% to transformational outperformed their peers. This became the 70-20-10 “rule” that every innovation consultant quotes.

What it does well: – Provides a concrete allocation framework. Not just “balance your portfolio” but “here are the percentages.” – Backed by empirical research, Nagji and Tuff analysed hundreds of companies. – Creates a benchmark. “What’s your current ratio? Is it intentional or accidental?”

Where most people get it wrong: – The 70-20-10 ratio is an average across many industries. It’s not a prescription. Nagji and Tuff themselves said ratios vary: consumer goods companies skewed 80-18-2, while mid-stage technology companies ran closer to 45-40-15. – Capital-intensive industries need different math entirely. When your “10% transformational” budget is €500K and a single manufacturing pilot costs €2M, the standard ratio breaks down. – Counting projects is not the same as counting investment. Fifteen “core” projects and two “transformational” projects is not a 15:2 ratio, the transformational projects might need five times the per-project investment. – Companies use the matrix once to justify their existing allocation, then forget about it. The value is in revisiting it quarterly.

I use the Innovation Ambition Matrix when companies need concrete allocation guidance, specifically when the CFO asks “how much should we spend on innovation?” It gives a research-backed starting point. But I always stress: the right ratio depends on your industry, your competitive position, and how much disruption pressure you’re facing.

For more depth, see How to Allocate Your Innovation Portfolio: Beyond the 70-20-10 Rule.

The BCG Matrix Applied to Innovation

The BCG Growth-Share Matrix, stars, cash cows, question marks, and dogs, was designed for corporate strategy, not innovation management. But it’s still used in portfolio discussions, particularly by boards who are familiar with it from their MBA days.

Where it’s useful for innovation: – Identifying cash cows that fund explore activities. “Product line A generates €12M in profit. Can we allocate 8% of that to transformational innovation?” – Highlighting “dogs” that should be retired to free up resources for new initiatives. – Familiar language for executive committees.

Where it breaks down: – The BCG Matrix evaluates market share and market growth, which don’t apply to early-stage innovation. An explore project doesn’t have market share yet. – It encourages premature judgment. An innovation project that’s a “question mark” might need two more years of testing before you can categorise it. – It biases toward measurables. Innovation projects that can’t show market data get classified as “dogs” and killed too early.

I almost never use the BCG Matrix for innovation portfolio management. I mention it because clients bring it up, and I’d rather explain why it’s the wrong tool for this question than let teams misapply it.

Which Framework When?

The honest answer: most companies need two or three of these frameworks at different moments. The Business Portfolio Map for the initial portfolio diagnosis. The Innovation Ambition Matrix for allocation decisions. Three Horizons for board communication. And a governance system, which no single framework provides, for the month-to-month work of managing the portfolio.

For the full comparison, see Business Portfolio Map vs Three Horizons vs BCG Matrix: Which Framework When.

Explore vs Exploit: The Central Tension in Every Portfolio

Every innovation portfolio management conversation eventually arrives at the same fundamental tension: explore vs exploit. The terminology comes from James March’s 1991 research paper, later developed by O’Reilly and Tushman into their theory of organizational ambidexterity.

In theory, every company understands the need for both. In practice, exploit wins. Always. Unless you design the system to prevent it.

What explore vs exploit looks like in industrial B2B

In a software company, “explore” might mean spending €50K on a three-person team building a prototype for six weeks. If it doesn’t work, you’ve lost two months and a modest budget.

In a packaging machinery company I worked with, “explore” meant committing €1.8M to develop a proof-of-concept for a subscription-based maintenance service. The technology investment alone required new sensor integration, a data platform, and a software layer none of their engineers had built before. The validation cycle was 14 months, not six weeks. And the team needed to be pulled from core product development, which meant the flagship product line lost three of its best engineers.

That’s the reality of explore in capital-intensive industries. The cost is higher, the timeline is longer, and the opportunity cost is visible to everyone. When the CEO looks at the quarterly numbers and sees that three senior engineers are working on something that won’t generate revenue for two years, the pressure to pull them back is enormous.

Structural separation works, contextual ambidexterity usually doesn’t

O’Reilly and Tushman’s research showed that structural separation, creating distinct units for explore and exploit with different processes, metrics, and leadership, outperformed contextual ambidexterity (asking the same teams to do both). My experience confirms this, especially in manufacturing.

When an engineering team is responsible for both maintaining the current production line (exploit) and developing next-generation products (explore), the production line wins. Every time. Because the production line has customers who call when something breaks. The explore project has a PowerPoint deck and a hypothesis.

I worked with a chemical company that tried contextual ambidexterity for three years. The innovation team was embedded within the business units. Result: they spent 85% of their time on incremental product improvements that the business unit leaders requested, because those leaders controlled their performance reviews. The transformational portfolio was four projects on paper; in practice, none had progressed past initial market research.

We restructured. Created a separate innovation unit reporting to the CEO, with a ring-fenced budget and a separate governance board. Within 18 months, the portfolio had two projects in pilot phase and one that was generating early revenue from an adjacent market segment. Same people, same ideas, different structure.

The structure didn’t make the ideas better. It protected them from the gravitational pull of exploit.

For the full guide on this tension, see Explore vs Exploit: Balancing Innovation and Core Business.

How to Build Your Innovation Portfolio: A Step-by-Step Process

Here’s the process I use when a company asks me to help them get a handle on their innovation portfolio. It takes eight to twelve weeks for the initial setup, and then transitions to an ongoing governance rhythm.

Step 1: Map what you actually have

Before deciding where to go, you need to know where you are. This sounds obvious, but most companies don’t have a clear view of their full innovation portfolio. Projects live in different business units, on different spreadsheets, with different reporting structures.

I start by collecting every innovation initiative across the organisation, from the official R&D roadmap to the “skunkworks” projects that individual teams are running without formal approval. This inventory usually surprises leadership. One manufacturing client thought they had 8 innovation projects. The actual count was 23, including 6 that overlapped significantly and 3 that nobody could explain the purpose of.

For each initiative, I capture: business model (or hypothesis), current stage, investment to date, investment needed, team size, expected timeline, and evidence strength (how much do we actually know vs. assume?).

Step 2: Plot the portfolio

Using the Business Portfolio Map, I plot each initiative based on innovation risk and expected return. This creates the visual that typically triggers the “aha” moment in leadership teams.

The conversation usually goes something like: “We have 23 projects, and 19 of them are in the exploit zone. Our entire explore pipeline is four ideas, two of which haven’t been tested with a single customer.”

That visual imbalance is more persuasive than any strategy presentation. Leaders can see the problem.

Step 3: Diagnose the gaps

With the portfolio mapped, I diagnose using four questions:

Balance: What percentage of investment goes to core, adjacent, and transformational? How does that compare to what your competitive situation requires?

Coverage: Are you exploring in the markets and technologies that matter most for your future? Or are your explore projects clustered in safe, familiar territory?

Evidence: How many of your explore projects have been validated through testing business ideas rather than just internal enthusiasm? A portfolio full of untested ideas is a portfolio full of speculation.

Governance: Do you have a system for reviewing, advancing, pivoting, or killing these projects? Or do they drift until someone notices?

Step 4: Set allocation targets

Based on the diagnosis, set explicit allocation targets. Not just percentages, actual euros or budget hours by innovation type.

I generally start with the Innovation Ambition Matrix as a baseline and adjust for industry context. A packaging equipment manufacturer facing minimal disruption pressure might run 80-15-5. A chemical company watching digital competitors enter their distribution chain might need 60-25-15.

The critical move: get the CFO to sign off on protected budgets for explore. Not “whatever’s left after core gets funded.” A specific, ring-fenced amount that cannot be reallocated to exploit without explicit board approval.

Step 5: Build the governance system

This is where most companies stop, they do steps 1-4 in a strategy workshop, produce a beautiful portfolio map, and then go back to managing projects individually. The map sits in a drawer. Nothing changes.

The governance system is what makes portfolio management operational. It includes:

• Monthly evidence reviews: Teams present experiment results, not progress updates. What did you test? What did you learn? What are you testing next?
• Quarterly allocation decisions: Does the portfolio still match the strategy? Do any projects need more funding, less funding, or a kill decision?
• Annual portfolio rebalancing: Full review of allocation targets, competitive dynamics, and strategic direction.
• Kill criteria defined upfront: Every explore project enters the portfolio with explicit criteria for when it should be stopped. Not “if it doesn’t work”, specific metrics: “If fewer than 3 out of 10 target customers agree to a pilot by month 9, we stop.”

For more on governance, see Innovation Portfolio Governance: Running Review Meetings That Actually Work.

Innovation Portfolio Governance: Where Most Companies Fail

I need to be direct about something: the governance system is more important than the frameworks. You can use the wrong portfolio framework and still manage innovation effectively if your governance is strong. You can use the right framework and fail completely if your governance is weak.

What bad governance looks like

Portfolio reviews that are actually presentation contests. The team with the best slides gets funded. The team with the most honest assessment of problems gets questioned. This rewards optimism and punishes transparency, exactly the opposite of what explore projects need.

Monthly reviews where teams report on activities (we ran three experiments, we had twelve customer meetings) instead of outcomes (we validated two assumptions, we invalidated one, and we need to pivot the revenue model).

Annual reviews where the portfolio map gets updated but no projects get killed. Everything continues. Every explore project gets “one more quarter” because nobody wants to be the person who killed an idea.

No decision rights. Nobody knows who can approve additional funding for an explore project or who can kill a project that’s not meeting its criteria. Decisions get escalated to the CEO, who is too busy with exploit priorities to engage.

What good governance looks like

Evidence-based reviews. Teams present experiment results using a structured format: assumption tested, experiment run, result observed, decision made. Not feelings about progress, data about what they learned. This connects directly to innovation accounting from the testing silo: the metrics that matter for explore projects are learning velocity, evidence strength, and risk reduction, not revenue and ROI.

Pre-committed kill criteria. Every project enters the portfolio with explicit conditions under which it will be stopped. “If we can’t achieve problem-solution fit with at least 3 paying customers within 12 months and €150K, we stop.” This removes the emotional weight from kill decisions. The criteria were set when everyone was objective, before anyone was emotionally invested.

For more on kill decisions, see How to Kill Innovation Projects (Without Killing Innovation).

Separate governance for explore and exploit. This is the structural ambidexterity principle applied to governance. Explore projects should not be reviewed in the same meetings, with the same criteria, by the same people as exploit projects. An explore project that spent €80K and invalidated its core assumption had a productive quarter. Evaluating it alongside an exploit project that delivered €2M in margin improvements makes the explore team look like it wasted money.

Clear decision authority. Define who can approve what: project lead can spend up to €20K on experiments without approval. Innovation board can approve up to €200K per stage-gate. Executive committee approves anything above that. Fast decisions prevent explore projects from dying in committee.

Innovation Portfolio Management for Manufacturing and Industrial B2B

This is where I have the strongest opinion and the most direct experience. Most portfolio management advice is written for software companies, venture-backed startups, or corporate innovation labs at tech companies. Manufacturing is different.

Capital intensity changes the portfolio math

When Eric Ries talks about “build-measure-learn,” he’s thinking about code that costs time but not capital. In manufacturing, building means tooling. Tooling means €500K to €2M before you have a single prototype.

This changes how you manage the portfolio:

• Fewer explore projects, larger bets. A software company can run 20 explore experiments for €500K total. A manufacturer might afford three.
• Longer validation cycles. A physical product can’t be A/B tested in two weeks. Validation might require prototype tooling, regulatory testing, and customer field trials. Twelve to eighteen months is typical.
• Higher kill costs. When you’ve spent €800K on tooling for an explore project, the psychological and financial cost of killing it is much higher than abandoning a software prototype. This makes governance even more important, and kill criteria even more critical to set upfront.

I worked with an agricultural equipment manufacturer that was running five explore projects simultaneously. Total portfolio burn rate: €3.2M per year. After we mapped the portfolio and applied evidence-based governance, we killed two projects that had been running for over a year without meaningful customer validation. One had spent €620K exploring a precision farming add-on that farmers said they wanted in surveys, but none had agreed to a paid trial. The kill freed budget and engineering capacity for the three projects that had real evidence of customer demand.

That €620K was a painful write-off. But continuing to fund it would have cost another €800K over the next year for a project with no validated demand. The governance system made the decision possible. Without pre-set kill criteria, that project would have continued for another year on momentum and good intentions.

Regulated industries add another layer

Pharmaceutical, medical devices, food processing, chemical production, these industries face regulatory approval processes that add 6-18 months and significant cost to any innovation. Your portfolio management needs to account for regulatory timelines, not just market timelines.

This means explore projects need to be started earlier than in unregulated industries. If regulatory approval takes a year, and you start exploring too late, you’re always behind. The portfolio needs to include “regulatory runway” in its planning, how much time between validation and market entry?

Multi-stakeholder complexity

In B2B manufacturing, the person who wants the product is rarely the person who buys it. The plant manager wants the new equipment. The procurement director evaluates the vendor. The CFO approves the capital expenditure. The safety engineer needs to certify it.

Your portfolio management needs to reflect this. An explore project that has validated desirability with plant managers but hasn’t tested procurement feasibility or capital expenditure approval is further from market than it appears. I include stakeholder coverage as an explicit metric in portfolio reviews: which stakeholders have we tested with, and which decision-makers haven’t been consulted?

For the full industry guide, see Innovation Portfolio Management for Manufacturing Companies.

The Mistakes I See Over and Over

After 25 years and more than 40 portfolio reviews, the patterns are consistent. Here are the mistakes that waste the most money and the most time.

Mistake #1: The 95/5 illusion

Leadership declares that innovation is a strategic priority. The annual report mentions it. The CEO gives speeches about it. But the actual budget allocation is 95% exploit, 5% explore. The 5% is enough to fund a small team and some presentations, but not enough to validate a single business model in a capital-intensive industry.

The fix is not convincing leadership to care about innovation. They already care. The fix is protected budgets with explicit allocation targets that the CFO has signed off on. “Innovation is a priority” is a statement. “8% of the product development budget is ring-fenced for explore projects, governed by the innovation board” is a commitment.

Mistake #2: No kill criteria

I covered this in the governance section, but it deserves its own entry here because it’s the most damaging pattern I see. Without kill criteria, mediocre projects live forever. They consume budget, engineer time, and management attention. They block better ideas from entering the portfolio. And they give innovation a bad reputation internally, “see, we fund these explore projects and nothing ever comes of them.”

The reality is that nothing comes of them because nobody ever decides to stop them. They don’t succeed and they don’t fail. They linger.

Every explore project should have explicit kill criteria before it receives its first euro.

For the detail on how to set these criteria, see How to Kill Innovation Projects (Without Killing Innovation).

Mistake #3: Portfolio reviews as presentation theatre

Portfolio review meetings where teams present their progress using polished slide decks are not governance. They’re performance reviews. The team with the best presenter gets funded. The team with the most honest assessment of what went wrong gets scrutinised.

Real portfolio governance requires structured evidence presentation. What assumption did you test? What was the experiment? What was the result? How does this compare to your pre-set criteria? This format rewards learning and penalises spin. It’s uncomfortable at first. But it produces better portfolio decisions.

Mistake #4: Managing explore like exploit

Explore projects need different metrics, different governance, different timelines, and different expectations than exploit projects. When companies apply exploit management practices to explore projects, demanding quarterly revenue projections, requiring detailed three-year business plans, expecting predictable milestones, the explore projects either game the system (producing fictional projections) or get killed for not meeting criteria that shouldn’t apply.

The right metrics for explore projects come from innovation accounting.

The right metrics for explore projects are learning velocity, assumption validation rate, evidence strength progression, and cost-per-learning. Not revenue, not margin, not market share.

Mistake #5: Mapping the portfolio once and stopping

I’ve lost count of how many companies have done a portfolio mapping workshop, produced a nice Business Portfolio Map, shared it with the leadership team, and then never updated it. The map becomes a historical document. It shows what the portfolio looked like six months ago. It doesn’t drive decisions today.

Portfolio management is a continuous governance practice, not a workshop deliverable. The map should be updated at every quarterly review. Projects move, assumptions get validated or invalidated, and competitive dynamics shift. A portfolio map that’s more than three months old is decoration, not management.

For the full list of portfolio failure patterns, see Innovation Portfolio Mistakes: Why Most Companies Fund the Wrong Projects.

Frequently Asked Questions

What is innovation portfolio management?

Innovation portfolio management is the practice of managing all of a company’s innovation initiatives as a coordinated portfolio. Rather than evaluating each project individually, portfolio management looks at the entire collection: the balance between core improvements and exploratory bets, the total investment allocated by innovation type, the governance systems that decide which projects advance and which get killed, and the strategic alignment of the portfolio with the company’s future direction. The goal is ensuring that the portfolio as a whole creates long-term value, not just that individual projects meet their milestones.

How do you manage an innovation portfolio?

Start by mapping every innovation initiative in the company, official and unofficial. Plot them using a portfolio framework like the Business Portfolio Map (by risk and return) or the Innovation Ambition Matrix (by core, adjacent, and transformational). Diagnose gaps in balance, coverage, and evidence. Set explicit allocation targets and protect explore budgets. Build a governance system with monthly evidence reviews, quarterly allocation decisions, and pre-set kill criteria for every project. The key is making this an ongoing practice, not a one-time exercise. Portfolio management that only happens at annual strategy offsites isn’t portfolio management, it’s portfolio observation.

What is the Business Portfolio Map?

The Business Portfolio Map is a visual tool created by Alexander Osterwalder and the Strategyzer team, introduced in The Invincible Company (2020). It plots each business model in a company’s portfolio based on two axes: expected return and innovation risk. The result shows where business models sit on a spectrum from proven cash generators (high return, low risk) to early-stage explore bets (low return, high risk). It’s useful for creating a shared view of the portfolio and identifying imbalances. The limitation is that it’s a diagnostic tool, not a governance system, it shows you the problem but doesn’t tell you how to manage it over time.

For a full practitioner assessment, see What Is the Business Portfolio Map?.

How do you balance explore and exploit in innovation?

Through structural separation and protected budgets. Research by O’Reilly and Tushman shows that structurally separating explore and exploit units, with different teams, metrics, governance, and leadership, outperforms asking the same teams to do both. In practice, this means creating an explore unit with a ring-fenced budget that cannot be raided by exploit priorities, a separate governance board that evaluates projects on learning and evidence rather than revenue, and a reporting line that protects explore teams from quarterly performance pressure. The balance isn’t a one-time decision, it requires ongoing governance that adjusts allocation based on competitive dynamics, strategic shifts, and what the portfolio’s explore projects are learning.

What is the 70-20-10 rule in innovation?

The 70-20-10 rule comes from Nagji and Tuff’s 2012 Harvard Business Review article “Managing Your Innovation Portfolio.” It suggests allocating 70% of innovation resources to core improvements, 20% to adjacent expansions, and 10% to transformational bets. Their research showed that companies following roughly this ratio outperformed peers. But, and this is where most people stop reading, Nagji and Tuff found significant variation by industry. Consumer goods companies skewed 80-18-2. Mid-stage technology companies ran 45-40-15. The right ratio depends on your industry, competitive pressure, and disruption risk. Capital-intensive manufacturers often need different math entirely because the cost per explore project is so much higher. Use 70-20-10 as a starting point for the conversation, not as a formula.

How do you kill an innovation project?

With pre-committed criteria, not political negotiations. Before any explore project receives funding, define explicit conditions under which it will be stopped: “If we can’t achieve problem-solution fit with at least 3 paying customers within 12 months and €150K, we stop.” Set these when everyone is objective, before emotional and political attachment develops. At each portfolio review, compare results against criteria. If the criteria aren’t met, the decision has already been made. This removes the personal drama from kill decisions and makes stopping a normal part of portfolio governance rather than a failure event. Teams whose projects get killed should be celebrated for generating learning and redirected to new opportunities, not punished.

The details are in How to Kill Innovation Projects (Without Killing Innovation).

What is an ambidextrous organisation?

An ambidextrous organisation is one that can simultaneously exploit existing business models while exploring new ones. The concept was developed by Charles O’Reilly and Michael Tushman, who found that structural ambidexterity, creating separate units for explore and exploit with different processes, metrics, and leaders, outperforms contextual ambidexterity (asking the same people to do both). The separate units are integrated at the senior leadership level, where portfolio-level decisions are made about resource allocation between explore and exploit. In my experience, structural separation is especially important in manufacturing and industrial B2B, where the pressure from exploit (production, customers, operations) is intense and immediate, while explore benefits are uncertain and distant.

How do you measure innovation portfolio success?

Not with traditional financial metrics, at least not for the explore portion of the portfolio. Explore projects should be measured on innovation accounting metrics: learning velocity (how fast are we validating or invalidating assumptions?), evidence strength progression (are we moving from opinions to behavioural evidence?), risk reduction (how many critical assumptions have we resolved?), and cost-per-learning (how efficiently are we generating insights?). At the portfolio level, measure: balance (actual allocation vs. target allocation by innovation type), pipeline health (number of projects at each stage), kill rate (are you actually stopping projects that aren’t meeting criteria?), and innovation contribution (percentage of revenue from products launched in the last 3-5 years). The last metric, innovation contribution, is the ultimate measure. 3M famously targeted 25% of revenue from products launched within the previous five years.

What to Do Next

If you manage or influence an innovation portfolio, and if you’re reading this, you probably do, here’s where to start:

1. Audit your actual allocation. Not the budget labels, the real spending. What percentage of your innovation investment goes to core improvements vs. explore bets? The number will likely surprise you.
2. Map the portfolio visually. Use the Business Portfolio Map or a simple 2×2 matrix. Get every initiative on one page. Share it with your leadership team and watch the conversation shift.
3. Set kill criteria for your explore projects. Every explore initiative should have explicit conditions for stopping. If they don’t have those criteria today, set them this month.
4. Build a governance rhythm. Monthly evidence reviews. Quarterly allocation decisions. Annual rebalancing. Without governance, portfolio management is a workshop exercise, not a management discipline.

Innovation portfolio management is only possible once the organizational foundations are in place. Without leadership commitment, protected resources, and an incentive system that rewards explore work differently from exploit work, a portfolio governance system has nothing to govern. If you’re not sure whether your organization has those foundations, start with the Innovation Readiness Assessment before designing a portfolio management system.